Alleviation of abnormal synaptic neurotransmitter release by cell-permeable form of the truncated SNAP-25 upon transcutaneous delivery

Neurosci Lett. 2013 May 24:543:52-7. doi: 10.1016/j.neulet.2013.02.055. Epub 2013 Apr 2.

Abstract

Abnormal releases of neurotransmitters result in movement disorders such as dystonia, chorea, tics, blepharospasm and wrinkle formation, and intra-muscular injection of Botulinum neurotoxin is widely used for the treatment of these complications. But it is potentially poisonous and must be intra-muscularly injected with precision by a well-trained physician. For novel therapeutic development with high safety profile and easy skin penetration for these complications, we generated Trans-X, a cell permeable form of the truncated SNAP-25 that is one of the SNARE complex for vesicle exocytosis of neuron. Upon topical administration, Trans-X efficiently penetrated through skin, reached the dermis layer and remained stable. Trans-X, which did not show any ocular or skin allergic sensitivity, can block the pre-synaptic neurotransmitter transport via acting as a competitive inhibitor of SNARE complex formation, and effectively induced muscle paralysis comparable to BOTOX(®) evaluated by measuring compound muscle action potential. Topical treatment of the facial skin with Trans-X in clinical study can prevent the wrinkle formation and improve the skin roughness. Therefore, our study suggests that Trans-X may be a convenient and effective medical and cosmetic treatment for local management of movement disorder without systemic toxicity.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Administration, Cutaneous
  • Adult
  • Animals
  • Catecholamines / metabolism*
  • Cell Line
  • Cell Membrane Permeability
  • Drug Hypersensitivity / etiology
  • Female
  • Humans
  • In Vitro Techniques
  • Keratinocytes / metabolism
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Middle Aged
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / physiopathology
  • Neurotransmitter Agents / metabolism*
  • Paralysis / chemically induced
  • Protein Structure, Tertiary
  • Rabbits
  • Rats
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / pharmacology*
  • Skin Absorption / drug effects
  • Skin Aging / drug effects
  • Swine
  • Synapses / drug effects*
  • Synapses / metabolism
  • Synaptosomal-Associated Protein 25 / adverse effects
  • Synaptosomal-Associated Protein 25 / genetics
  • Synaptosomal-Associated Protein 25 / pharmacology*

Substances

  • Catecholamines
  • Neurotransmitter Agents
  • Recombinant Fusion Proteins
  • Synaptosomal-Associated Protein 25